XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies for gout, progressive kidney disease, and other disorders linked to elevated uric acid and abnormal purine metabolism. Its current pipeline includes programs for gout, autosomal dominant polycystic kidney disease, acute kidney injury associated with respiratory virus infections, and type 2 diabetic nephropathy. The company’s research centers on uric acid-lowering and xanthine oxidase-targeted approaches designed to address conditions ranging from rare kidney diseases to broader metabolic and renal disorders. Based in Calgary, Canada, XORTX Therapeutics Inc. operates as a biotechnology and pharmaceutical developer with an emphasis on advancing drug candidates through clinical development and commercialization in specialized disease areas.
$1.24
-$0.18 (-12.68%)
EOD Oct 16, 2026
ROIC dropped from -81.04% to -93.59%, capital efficiency is deteriorating. Negative free cash flow of -$3M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$4M
▲ +19.8% YoY
Op. Margin
—
ROIC
-93.59%
▼ -12.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$5M
▲ +24.0% YoY
Op. Cash Flow (TTM)
-$5M
▲ +8.6% YoY
Net Debt
-$827K
Net Cash Position
Cash & Equiv.
$865K
Continue Research
Is XORTX Therapeutics (XRTX) overvalued?
XORTX Therapeutics (XRTX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, XORTX Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is XORTX Therapeutics a high-quality business?+
XORTX Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -93.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is XORTX Therapeutics a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh XRTX's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.